$CDXC
ChromaDex Corp. Stock $cdxc

$cdxc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017204 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$20.32M	$22.56M
YoY Change	21.46%	30.69%
Cost Of Revenue	$7.967M	$9.038M
YoY Change	19.09%	34.35%
Gross Profit	$12.36M	$13.52M
YoY Change	23.04%	28.35%
Gross Profit Margin	60.8%	59.93%
Selling, General & Admin	$13.31M	$14.29M
YoY Change	-12.36%	-16.83%
% of Gross Profit	107.7%	105.73%
Research & Development	$1.365M	$1.193M
YoY Change	9.64%	10.67%
% of Gross Profit	11.05%	8.83%
Depreciation & Amortization	$271.0K	$228.0K
YoY Change	3.44%	13.43%
% of Gross Profit	2.19%	1.69%
Operating Expenses	$14.67M	$15.49M
YoY Change	-10.69%	-15.21%
Operating Profit	-$2.316M	-$1.968M
YoY Change	-63.74%	-74.55%
Interest Expense	$125.0K	$66.00K
YoY Change	1150.0%	725.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.191M	-$1.902M
YoY Change	-65.75%	-75.43%
Income Tax
% Of Pretax Income
Net Earnings	-$2.191M	-$1.902M
YoY Change	-65.75%	-75.43%
Net Earnings / Revenue	-10.78%	-8.43%
Basic Earnings Per Share	-$0.03	-$0.03
Diluted Earnings Per Share	-$0.03	-$0.03
COMMON SHARES
Basic Shares Outstanding	74.97M shares	74.84M shares
Diluted Shares Outstanding	74.97M shares	74.80M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.25M	$22.99M
YoY Change	55.61%	10.56%
Cash & Equivalents	$26.30M	$23.00M
Short-Term Investments
Other Short-Term Assets	$2.037M	$2.447M
YoY Change	23.08%	15.81%
Inventory	$11.97M	$11.91M
Prepaid Expenses
Receivables	$8.918M	$9.221M
Other Receivables	-$2.800M	-$3.500M
Total Short-Term Assets	$46.38M	$46.57M
YoY Change	20.45%	4.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.680M	$6.041M
YoY Change	-16.26%	-13.61%
Goodwill
YoY Change
Intangibles	$591.0K	$630.0K
YoY Change	-22.03%	-22.03%
Long-Term Investments
YoY Change
Other Assets	$518.0K	$532.0K
YoY Change	-8.16%	-12.21%
Total Long-Term Assets	$6.789M	$7.203M
YoY Change	-16.24%	-14.32%
TOTAL ASSETS
Total Short-Term Assets	$46.38M	$46.57M
Total Long-Term Assets	$6.789M	$7.203M
Total Assets	$53.17M	$53.77M
YoY Change	14.07%	1.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.03M	$8.951M
YoY Change	-1.63%	-8.48%
Accrued Expenses	$8.079M	$8.610M
YoY Change	20.65%	5.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.00K	$17.00K
YoY Change	-23.08%	0.0%
Total Short-Term Liabilities	$19.06M	$18.42M
YoY Change	7.54%	-1.45%
LONG-TERM LIABILITIES
Long-Term Debt	$17.00K	$20.00K
YoY Change
Other Long-Term Liabilities	$6.943M	$7.308M
YoY Change	-14.39%	-12.57%
Total Long-Term Liabilities	$6.960M	$7.328M
YoY Change	-14.18%	-12.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.06M	$18.42M
Total Long-Term Liabilities	$6.960M	$7.328M
Total Liabilities	$26.02M	$25.75M
YoY Change	0.72%	-4.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$189.6M	-$187.4M
YoY Change	3.56%	6.07%
Common Stock	$75.00K	$74.00K
YoY Change	10.29%	8.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.15M	$28.02M
YoY Change
Total Liabilities & Shareholders Equity	$53.17M	$53.77M
YoY Change	14.07%	1.58%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.191M	-$1.902M
YoY Change	-65.75%	-75.43%
Depreciation, Depletion And Amortization	$271.0K	$228.0K
YoY Change	3.44%	13.43%
Cash From Operating Activities	$3.280M	$2.800M
YoY Change	-185.59%	-138.89%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$91.00K
YoY Change	-111.76%	-464.0%
Acquisitions
YoY Change
Other Investing Activities	$5.000K
YoY Change
Cash From Investing Activities	-$5.000K	-$91.00K
YoY Change	-94.12%	264.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	-$1.000K
YoY Change	150.0%	-66.67%
NET CHANGE
Cash From Operating Activities	3.280M	$2.800M
Cash From Investing Activities	-5.000K	-$91.00K
Cash From Financing Activities	-10.00K	-$1.000K
Net Change In Cash	3.265M	$2.700M
YoY Change	-183.27%	-137.37%
FREE CASH FLOW
Cash From Operating Activities	$3.280M	$2.800M
Capital Expenditures	$10.00K	$91.00K
Free Cash Flow	$3.270M	$2.709M
YoY Change	-187.27%	-137.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001386570
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37752
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CHROMADEX CORPORATION
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2940963
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10900 Wilshire Blvd
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
CY2023Q1	dei	City Area Code CityAreaCode	310
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	388-6706
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CDXC
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74966125	shares
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23141000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20441000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	499000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	122000	usd
CY2023Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	3500000	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	3100000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9221000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8482000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	11908000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	14677000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2295000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2967000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	46565000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	46567000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2689000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2799000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	630000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	671000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3352000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3523000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	532000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	497000	usd
CY2023Q1	us-gaap	Assets Assets	53768000	usd
CY2022Q4	us-gaap	Assets Assets	54057000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8951000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9679000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8610000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7337000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	697000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	680000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	17000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	16000	usd
CY2023Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	148000	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	157000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18423000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17869000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3955000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3955000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3353000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3539000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	25751000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25385000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74666000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74666000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74567000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74567000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	74000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	74000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	215367000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	214094000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-187424000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185493000	usd
CY2023Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	0	usd
CY2022Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-3000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28017000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	28672000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53768000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54057000	usd
CY2023Q1	us-gaap	Revenues Revenues	22556000	usd
CY2022Q1	us-gaap	Revenues Revenues	17259000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	9038000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	6727000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	13518000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	10532000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7874000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8237000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1193000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1078000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6419000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8949000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	15486000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18264000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1968000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7732000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	66000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-8000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1902000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74796000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74796000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68314000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68314000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	28672000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1273000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1902000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28017000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	31727000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1888000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25877000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1902000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	228000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	201000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	41000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	171000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	299000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1273000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1888000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	316000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1084000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1094000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2769000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1706000	usd
CY2023Q1	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	27000	usd
CY2022Q1	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	114000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-616000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-46000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-728000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-643000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1273000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1645000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-169000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2792000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7198000	usd
CY2023Q1	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	91000	usd
CY2022Q1	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	25000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-91000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2700000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7226000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20441000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28219000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23141000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20993000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	180000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	58000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of BusinessChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex International, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, Asia Pacific Scientific, Inc., ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex” or the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors.ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen®. The Company further develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. Additionally, the Company offers natural product fine chemicals, known as phytochemicals, and related research and development services.
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1900000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2800000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23000000	usd
CY2022Q1	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2023Q1	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1902000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74796000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74796000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68314000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68314000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	945000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	365000	shares
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
CY2023Q1	us-gaap	Revenues Revenues	22556000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	9038000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	13518000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7874000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1193000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6419000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	15486000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1968000	usd
CY2022Q1	us-gaap	Revenues Revenues	17259000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	6727000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	10532000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8237000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1078000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8949000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18264000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7732000	usd
CY2023Q1	us-gaap	Revenues Revenues	22556000	usd
CY2022Q1	us-gaap	Revenues Revenues	17259000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7088000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7901000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2744000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2992000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1500000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3284000	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	576000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	500000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	11908000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	14677000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3400000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4100000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	231000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	359000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	53000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	139000	usd
CY2023Q1	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	284000	usd
CY2022Q1	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	498000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	191000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	288000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	689000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	692000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1101000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1135000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	901000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	491000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	358000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	30000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4708000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	658000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4050000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	697000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3353000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.755
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.035
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Price SharePrice	1.53
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1273000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1888000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7000000	usd
CY2019Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	1600000	usd
CY2022Q3	cdcx	Other Income Net Employee Retention Credit Cares Act OtherIncomeNetEmployeeRetentionCreditCARESAct	2100000	usd
CY2022Q4	cdcx	Proceeds From Employee Retention Tax Credit Cares Act ProceedsFromEmployeeRetentionTaxCreditCARESAct	600000	usd
CY2023Q1	cdcx	Proceeds From Employee Retention Tax Credit Cares Act ProceedsFromEmployeeRetentionTaxCreditCARESAct	800000	usd
CY2023Q1	cdcx	Prepaid Expenses And Other Current Assets Employee Retention Credit Cares Act PrepaidExpensesAndOtherCurrentAssetsEmployeeRetentionCreditCARESAct	1000000	usd
CY2023Q1	cdcx	Accrued Expenses Employee Retention Credit Cares Act AccruedExpensesEmployeeRetentionCreditCARESAct	200000	usd

Files In Submission

Name	View Source	Status
cdcx-20230331_pre.xml	Edgar Link	unprocessable
0001628280-23-017204-index-headers.html	Edgar Link	pending
0001628280-23-017204-index.html	Edgar Link	pending
0001628280-23-017204.txt	Edgar Link	pending
0001628280-23-017204-xbrl.zip	Edgar Link	pending
cdcx-20230331.htm	Edgar Link	pending
cdcx-20230331.xsd	Edgar Link	pending
cdcx-20230331_g1.jpg	Edgar Link	pending
cdxcq1202310qex-311.htm	Edgar Link	pending
cdxcq1202310qex-312.htm	Edgar Link	pending
cdxcq1202310qex-321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
cdcx-20230331_cal.xml	Edgar Link	unprocessable
cdcx-20230331_lab.xml	Edgar Link	unprocessable
cdcx-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdcx-20230331_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXC
ChromaDex Corp. Stock $cdxc

2023 Q2 Form 10-Q Financial Statement

#000162828023017204 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC ChromaDex Corp. Stock $cdxc

2023 Q2 Form 10-Q Financial Statement

#000162828023017204 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC
ChromaDex Corp. Stock $cdxc